Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PetVivo Holdings Inc. Warrant (PETVW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/27/2025: PETVW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -20% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.85 | 52 Weeks Range 0.03 - 0.10 | Updated Date 06/22/2025 |
52 Weeks Range 0.03 - 0.10 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -301.45% |
Management Effectiveness
Return on Assets (TTM) -159.92% | Return on Equity (TTM) -8616.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 16029244 |
Shares Outstanding - | Shares Floating 16029244 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
PetVivo Holdings Inc. Warrant
Company Overview
History and Background
PetVivo Holdings, Inc. is a biomedical device company focused on commercializing innovative medical devices and therapeutics for companion animals. The warrants are derivatives related to the underlying common stock of PetVivo Holdings.
Core Business Areas
- Biomedical Devices: Development and commercialization of medical devices for pets, particularly focused on osteoarthritis treatment.
Leadership and Structure
Details on PetVivo's leadership and organizational structure would be required to fill this section accurately. Publicly available information should be consulted to find names, titles, and reporting lines.
Top Products and Market Share
Key Offerings
- Spryngu2122: An injectable osteoarthritis treatment for dogs. Market share data is not readily available. Competitors include traditional NSAIDs (nonsteroidal anti-inflammatory drugs) and other injectable osteoarthritis treatments like Adequan Canine (Luitpold Pharmaceuticals). Revenue from this product is not publically available.
Market Dynamics
Industry Overview
The veterinary orthopedic market is growing, driven by increased pet ownership and a greater willingness to spend on pet healthcare. There is increasing demand for less invasive treatments.
Positioning
PetVivo is positioned as a provider of innovative, injectable therapies for osteoarthritis in companion animals. Its advantage lies in potentially providing a longer-lasting solution with fewer side effects than traditional treatments.
Total Addressable Market (TAM)
The TAM for veterinary osteoarthritis treatments is estimated to be in the hundreds of millions of dollars annually. PetVivo is positioned to capture a share of this market with its Spryngu2122 product. Specific TAM data requires additional market research.
Upturn SWOT Analysis
Strengths
- Innovative product (Spryngu2122)
- Focus on a growing market
- Potential for improved efficacy and safety compared to alternatives
Weaknesses
- Limited market penetration
- Reliance on a single product
- Small company size and limited resources
- Warrant derivative risk
Opportunities
- Expansion into new markets and indications
- Partnerships with veterinary distributors and clinics
- Development of new products
- Capitalizing on increasing pet healthcare spending
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Potential for adverse events
- Economic downturn impacting pet healthcare spending
- Dilution from warrant exercises
Competitors and Market Share
Key Competitors
- Luitpold Pharmaceuticals (ADMS)
- Zoetis (ZTS)
- Elanco Animal Health (ELAN)
Competitive Landscape
PetVivo is a smaller player in a market dominated by larger, established pharmaceutical companies. Its competitive advantage lies in its innovative Spryngu2122 product, but it faces challenges in terms of market reach and resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require financial data over several years.
Future Projections: Future growth projections depend on factors like product adoption, market penetration, and competition. Analyst estimates are needed to provide specific projections.
Recent Initiatives: Recent strategic initiatives are required to fill this data.
Summary
PetVivo Holdings, Inc. is a biomedical device company focused on a niche market with its innovative Spryngu2122 product. While the product holds promise, the company faces challenges related to limited resources and competition from larger players. Successfully navigating regulatory hurdles and expanding market reach are crucial for future growth, while managing the financial complexity arising from warrants is important. The warrants themselves are highly speculative and their value is entirely dependent on the performance of the underlying stock, and are subject to significant risk.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is for informational purposes only and should not be construed as a recommendation to buy or sell any security. The value of warrants is highly volatile and speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PetVivo Holdings Inc. Warrant
Exchange NASDAQ | Headquaters Edina, MN, United States | ||
IPO Launch date 2021-08-11 | CEO, President & Director Mr. John Lai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 20 | Website https://www.petvivo.com |
Full time employees 20 | Website https://www.petvivo.com | ||
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Edina, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.